UPDATE : Monday, September 7, 2020
상단여백
Latecomer experimental drug no better than Dupixent in trial
Pharmaceutical firms have strived to make latecomer drugs to beat Dupixent ...
by Kim Yun-mi  |  2019-06-24 15:49
라인
Off-label use of Mabthera Inj. denied
The Health Insurance Review and Assessment Service (HIRA) said it has disap...
by Kim Yun-mi  |  2019-06-20 15:49
라인
‘Korean cancer researchers have risen to world-class level’
The Korean Cancer Study Group (KCSG) said Korean institutions and researche...
by Kim Yun-mi  |  2019-06-20 15:04
라인
‘Immunotherapies contributed to advancement of neoadjuvant cancer treatment’
Immunotherapies, less toxic than conventional cytotoxic chemotherapies, hav...
by Kim Yun-mi  |  2019-06-19 15:36
라인
AstraZeneca to invest $630 million in Korean biohealth sector
AstraZeneca said it would invest $630 million into Korea’s biotech and heal...
by Kim Yun-mi  |  2019-06-17 11:33
라인
‘Moon administration to expand investment into healthcare, quality of life’
The Moon Jae-in government will enhance the social safety net, build a life...
by Kim Yun-mi  |  2019-06-14 16:49
라인
Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug
Korean patients with severe atopic dermatitis gathered in front of the Nati...
by Kim Yun-mi  |  2019-06-12 13:29
라인
Forxiga prevents kidney disease in diabetes patients
AstraZeneca’s sodium-glucose cotransporter-2 (SGLT2) inhibitor Forxiga (ing...
by Kim Yun-mi  |  2019-06-11 15:40
라인
HIV prevention pill to get insurance benefit in Korea
The local medical community is likely to use a drug to prevent HIV infectio...
by Kim Yun-mi  |  2019-05-30 13:25
라인
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
Oncology researchers around the world are paying keen attention to MDM2 (mo...
by Kim Yun-mi  |  2019-05-29 12:35
라인
‘Enstilum treats all psoriasis from mild to severe ones’
Enstilum Foam (betamethasone dipropionate/calcipotriol), a foam-type treatm...
by Kim Yun-mi  |  2019-05-28 14:44
라인
‘Risk-sharing agreements back up economic feasibility review’
An expert said expanding risk-sharing agreements (RSA) and introducing a po...
by Kim Yun-mi  |  2019-05-22 14:46
라인
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too?
Japan’s Health Ministry warned that Eli Lilly’s breast cancer therapy Verze...
by Kim Yun-mi  |  2019-05-21 14:19
라인
Low-income, single women more vulnerable to osteoporosis
Women who are living by herself, earning low incomes, and having poor knowl...
by Kim Yun-mi  |  2019-05-20 15:40
라인
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride
The Korean Diabetes Association (KDA)’s revised guideline for diabetes trea...
by Kim Yun-mi  |  2019-05-15 15:30
라인
Keytruda wins nod as adjuvant therapy after melanoma surgery
The Ministry of Food and Drug Safety has approved PD-1 inhibitor immunother...
by Kim Yun-mi  |  2019-05-15 14:14
라인
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon
With Roche’s HER2-positive breast cancer drug Herceptin (trastuzumab) facin...
by Kim Yun-mi  |  2019-05-13 14:23
라인
Xeljianz is easier to use than biologic therapies -- is it safer, however?
Pfizer’s Xeljianz (tofacitinib), an oral Janus kinase (JAK) inhibitor to tr...
by Kim Yun-mi  |  2019-05-10 15:34
라인
[Exclusive] MSD Korea playing tricks to reduce daycare cost
Korea Biomedical Review ran an exclusive story on an executive at MSD Korea...
by Kim Yun-mi  |  2019-05-09 11:20
라인
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too
Immunotherapies have become so effective and popular that some cancer patie...
by Kim Yun-mi  |  2019-05-07 14:30
여백
여백
여백
Back to Top